What does it mean that a vision correction procedure costs twice as much as LASIK but ophthalmologists are recommending it more frequently — not because it’s more profitable, but because the outcomes data are genuinely impressive? The EVO Implantable Collamer Lens (ICL) is FDA-approved, reversible, doesn’t remove corneal tissue, and handles high prescriptions that fall outside LASIK’s safe range. The price tag is real. So is the technology. Here’s how to evaluate whether it’s the right call for your situation.
EVO ICL vs. LASIK: A Fundamental Difference
LASIK reshapes your cornea with a laser — permanently and irreversibly — to correct your vision. The EVO ICL does something different: a thin, soft lens (made from Collamer, a collagen-copolymer material) is surgically placed between your iris and your natural lens, inside the eye. No corneal tissue is removed. Your natural lens remains. The ICL sits invisibly behind your pupil and corrects your vision from there.
This approach has two major clinical advantages:
- Corneas too thin for LASIK stay untouched. If your corneal thickness or topography doesn’t support safe LASIK ablation, ICL is often the only surgical vision correction option.
- High prescriptions handled safely. EVO ICL is FDA-approved for myopia up to -20.00 diopters. LASIK’s safe treatment range typically tops out around -8.00 to -10.00 diopters, depending on corneal thickness. For patients at -12.00 or -15.00, ICL is often the only option that can achieve full correction.
What You’ll Pay
| Cost Component | Estimated Range | Notes |
|---|---|---|
| EVO ICL procedure (per eye) | $3,500–$6,000 | Most practices price per eye |
| Both eyes total | $7,000–$12,000 | Average around $8,000–$10,000 |
| Pre-operative evaluation | $200–$400 | Required; often credited toward procedure |
| Post-operative medications | $100–$200 | Included at some practices, not others |
| LASIK (for comparison) | $2,000–$3,500/eye | Both eyes $4,000–$7,000 |
| Premium custom LASIK | $2,500–$3,500/eye | Closer to ICL for high-prescription candidates |
| Enhancement/lens exchange (if needed) | $1,500–$3,000 | Rare; ICL is adjustable/removable |
The EVO ICL is significantly more expensive than LASIK. The premium reflects the lens itself (a precision-manufactured custom device), the intraocular surgical complexity (this is inside the eye, not a surface procedure), and the lower volume of procedures — meaning less equipment amortization per patient.
Why Ophthalmologists Recommend It Beyond “LASIK Isn’t an Option”
The case for EVO ICL isn’t limited to patients who can’t have LASIK. Several outcome advantages apply:
Quality of vision: Multiple published studies report favorable comparison to LASIK for visual quality metrics, particularly contrast sensitivity and night vision performance. A 2022 review in the Journal of Refractive Surgery found ICL patients reported high satisfaction rates comparable to or exceeding LASIK in quality-of-vision measures.
Dry eye: ICL doesn’t disrupt corneal nerves the way LASIK does. Post-operative dry eye is substantially less common and less severe after ICL than after LASIK. For patients with borderline or existing dry eye, this difference is clinically meaningful.
Reversibility: If your vision changes significantly, if a better technology emerges, or if you need cataract surgery decades later, the ICL can be removed or exchanged. No corneal tissue has been permanently reshaped.
The American Academy of Ophthalmology notes that ICL procedures have increased significantly in the US following the FDA approval of the EVO+ (larger ICL) version, which improves aqueous flow and eliminates the need for pre-operative laser iridotomy that earlier ICL versions required.
ICL candidacy requires:
- Adequate anterior chamber depth (the space between your cornea and natural lens) — typically 3.0mm or more
- No cataracts or early cataract formation — if you’re in your late 50s or 60s, your surgeon may recommend refractive lens exchange instead
- No active glaucoma or uveitis
- Stable prescription for at least 1 year
- Pupil size compatible with the lens diameter
If your anterior chamber is shallow or you have early lens changes, ICL isn’t appropriate and your surgeon will tell you directly. The pre-operative evaluation (Pentacam imaging, specular microscopy, anterior segment OCT) determines fit. Don’t try to push ICL if the anatomy doesn’t support it.
Insurance and Payment Options
No commercial insurance plan covers EVO ICL as of 2025 — it’s classified as elective refractive surgery. HSA and FSA funds are eligible for use and represent a meaningful tax-advantaged way to pay. CareCredit and Alphaeon Credit offer 12–24 month deferred interest or low-interest financing options used widely by ICL patients.
Some practices offer bundled pricing with interest-free payment plans for 6–12 months. For a $9,000 procedure spread over 12 months, you’re looking at $750/month — comparable to financing a used car.
Military personnel often pursue ICL rather than LASIK because the intraocular procedure has no flap-related dislodgement concerns. Some military laser surgery centers now offer ICL as an on-base option, with significant fee reductions for active-duty members.
EVO ICL is an intraocular procedure — it involves an incision inside your eye. The risks are extremely low when performed by an experienced surgeon, but they’re different from LASIK’s risks. Endophthalmitis (intraocular infection) is rare but more serious than anything that can happen with corneal laser surgery. Cataract development — a small risk from the lens touching the natural lens — was more common with older ICL designs; the EVO design significantly reduces this. Ask your surgeon specifically about their endophthalmitis rate, cataract rate, and vault outcomes in their EVO ICL cases before proceeding.
Bottom Line
EVO ICL costs $7,000–$12,000 for both eyes — roughly $3,000–$5,000 more than equivalent-tier LASIK. For patients who aren’t LASIK candidates (thin corneas, high prescriptions), it’s the right choice and the extra cost isn’t really a choice — it’s the only surgical path. For eligible candidates who choose ICL for quality-of-vision or dry eye reasons, the premium buys a reversible, cornea-sparing procedure with comparable or better outcomes than LASIK in the right hands.